BioNexus Gene Lab Corp
For the period ended Dec 31, 2025. Filed Apr 14, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Apr 14, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 11. Executive Compensation
Summary Executive Compensation Table
The following table reflects the Summary Compensation for our named Executive Officers for fiscal years ended December 31, 2025 and 2024, respectively. For such periods, there were no bonus, non-equity plan compensation, nonqualified compensation earnings or other compensation other than as stated below for the named executive officers.
| Name and principal position | Year | Fee | Salary | Bonus | Stock Awards | Option Awards | Non-Equity Incentive Plan Compensation | Nonqualified Deferred Compensation Earnings | All Other Compensation | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| ($) · ($) · ($) · ($) · ($) · ($) · ($) · ($) · ($) | ||||||||||
| Su-Leng Tan Lee | 2025 | 12,000 | 434,019 | - | - | - | - | - | - | 446,019 |
| Chief Executive Officer | 2024 | 12,000 | 478,126 | 1,000 | - | - | - | - | - | 491,126 |
| Set Fui Chong (1) Chief Financial Officer | 2025 | - | 22,664 | - | - | - | - | - | - | 22,664 |
(1) Ms Set Fui Chong began her employment with the Company on June 17, 2025.
Employment Agreements
Employment Agreement between Mr. Su-Leng Tan Lee and the Company
Effective as of August 15, 2023, the Company entered into an employment agreement with Mr. Su-Leng Tan Lee. The agreement provides for an annual base salary. Mr. Tan Lee’s employment will terminate two years from the effective date of the agreement, and such term shall be automatically extended for a one-year term thereafter at the Company’s request. The agreement has been extended by the Company through July, 2026. The agreement further provides that either party to the agreement may terminate Mr. Tan Lee’s employment upon one month’s prior written notice. Additionally, the agreement provides that Mr. Tan Lee shall not, during the term of the agreement and for 24 months after cessation of employment, carry on business in competition with the Company.
Employment Agreement between Ms. Set Fui Chong and the Company
Effective as of June 17, 2025, the Board of Directors of BGLC appointed Ms Chong Set Fui (Angeline) as the Company’s Chief Financial Officer and Principal Financial Officer, effective immediately. Ms. Chong will concurrently serve as Chief Financial Officer of the Company’s wholly owned subsidiary, MRNA Scientific Sdn. Bhd. and will perform the responsibilities of the Principal Financial Officer of BioNexus Gene Lab Corp. in accordance with U.S. federal securities laws and Nasdaq rules. Under the terms of her employment agreement, Ms. Chong will receive a monthly salary of RM15,000 (approximately USD $3,500), plus benefits including medical coverage, fuel allowance, and eligibility for discretionary bonus compensation. The agreement began on June 17, 2025 and terminates on June 16, 2027. Ms. Chong has over 25 years of Senior financial leadership experience, including serving as the Chief Financial Officer of Avillion Berhad from 2013 until November 2024. She is a member of the of the Malaysia Institute of Accountants (MIA) and Association of Chartered Certified Accountants (ACCA), and brings deep expertise in corporate financial reporting, internal controls, and regional operations oversight.
Concurrent with the new appointment, Mr. Su-Leng Tan Lee ceased his role as acting Chief Financial Officer and Principal Financial Officer of the Company.
Grants of Plan-Based Awards
As of December 31, 2025, there were no outstanding plan-based awards attributable to any executive officer.
Outstanding Equity Awards at Fiscal Year End
As of December 31, 2025 there were no outstanding equity awards attributable to any executive officer.
Option Exercises and Stock Vested
As of December 31, 2025, there were no option exercises or stock vesting attributable to any executive officer.
Pension Benefits
As of December 31, 2025, there were no pension benefits attributable to any executive officer.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.